Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May 20:7:87-102.
doi: 10.4137/CMO.S7633. Print 2013.

Targeted therapies in the treatment of advanced hepatocellular carcinoma

Zhengyu Wei  1 , Cataldo Doria, Yuan Liu
Affiliations

Targeted therapies in the treatment of advanced hepatocellular carcinoma

Zhengyu Wei et al. Clin Med Insights Oncol. .

Abstract

Hepatocellular carcinoma (HCC) is the most common liver cancer and the third leading cause of cancer death. It has been a major worldwide health problem with more new cases being diagnosed each year. The current available therapies for patients with advanced HCC are extremely limited. Therefore, it is of great clinical interests to develop more effective therapies for systemic treatment of advanced HCC. Several promising target-based drugs have been tested in a number of clinical trials. One breakthrough of these efforts is the approved clinical use of sorafenib in patients with advanced HCC. Targeted therapies are becoming an attractive option for the treatment of advanced HCC. In this review, we summarize the most recent progress in clinical targeted treatments of advanced HCC.

Keywords: hepatocellular carcinoma (HCC); signaling pathway; sorafenib; targeted therapy; tumor inhibitor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diagram of signaling pathways stimulated by ligand binding to the tyrosine kinase receptor.
Figure 2
Figure 2
Mechanisms of epigenetic regulation in cancer gene expression. Abbreviations: HAT, histone acetyltransferase; HDAC, histone deacetylase; miRNA, microRNA; DNMT, mammalian DNA methyltransferase.
Figure 3
Figure 3
Molecular action of targeted agents in tyrosine kinase receptors and the corresponding signaling pathways. (A) Agents against tyrosine kinase receptors or ligands. (B) Agents against targets in signaling pathways.
See this image and copyright information in PMC

References

    1. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36(5 Suppl 1):S74–83. - PubMed
    1. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomedl Sci. 2008;15(2):137–45. - PubMed
    1. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008;7(3):237–57. - PubMed
    1. Cabrera R, Nelson DR. Review article: management of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;31(4):461–76. - PubMed
    1. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126(2):460–8. - PubMed

LinkOut - more resources